Ignite Creation Date:
2024-05-05 @ 12:10 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00261287
Status:
COMPLETED
Last Update Posted:
2016-11-30
First Post:
2005-12-02
Brief Title:
Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis 2-5 Years Old BY9010M1-416
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Parallel-Group Clinical Trial Designed to Assess the Safety and Tolerability of Ciclesonide 200 mcg Once Daily Applied as a Nasal Spray for Twelve Weeks in the Treatment of Perennial Allergic Rhinitis PAR in Pediatric Patients 2-5 Years of Age
Status:
COMPLETED
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of ciclesonide nasal spray for long term use in relieving symptoms in perennial allergic rhinitis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None